奥拉帕利联合局部区域放疗治疗头颈部鳞状细胞癌的Ⅰ期可行性研究
单中心Ⅰ期剂量递增试验评估PARP抑制剂奥拉帕利联合放疗治疗头颈部鳞状细胞癌的最大耐受剂量。剂量Ⅰ级(奥拉帕利25 mg每日两次联合加速放疗)4例中3例出现剂量限制性毒性,降至剂量Ⅱ级(25 mg每日一次联合常规分割放疗)后5例均未出现剂量限制性毒性,确定为最大耐受剂量。中位随访60个月,4年局部区域控制率和总生存率分别为77.8%和88.9%。
要点
- 剂量Ⅰ级奥拉帕利25 mg每日两次联合加速放疗(70 Gy/6周)4例中3例出现剂量限制性毒性。
- 剂量Ⅱ级奥拉帕利25 mg每日一次联合常规分割放疗(70 Gy/7周)5例均未出现剂量限制性毒性,确定为最大耐受剂量。
- 中位随访60个月,4年局部区域控制率77.8%,总生存率88.9%。
核心结论
- 奥拉帕利25 mg每日一次联合常规分割放疗耐受良好并被确定为最大耐受剂量,而奥拉帕利25 mg每日两次联合加速放疗时观察到严重剂量限制性毒性。
- 作者认为该联合方案可在不适合顺铂为基础放化疗的局部晚期头颈部鳞状细胞癌患者的未来奥拉帕利剂量递增研究中进一步探索。
研究设计与样本
- 单中心Ⅰ期剂量递增试验,旨在确定PARP抑制剂奥拉帕利联合放疗治疗头颈部癌患者的最大耐受剂量。
- 最大耐受剂量定义为不超过20%患者出现剂量限制性毒性的最高剂量水平,或在无剂量限制性毒性时达到的最高剂量。
- 所有患者在开始放疗前先接受一周奥拉帕利单药治疗(25 mg每日一次)。
- 剂量Ⅰ级为奥拉帕利25 mg每日两次联合加速放疗(70 Gy/35次,6周),因4例中3例出现剂量限制性毒性而降级至剂量Ⅱ级。
- 剂量Ⅱ级为奥拉帕利25 mg每日一次联合常规分割放疗(70 Gy/7周),共治疗5例。
主要发现
- 剂量Ⅰ级4例中3例出现剂量限制性毒性:急性气管切开分别在治疗后5个月和7个月,放射性骨坏死在治疗后7个月。
- 剂量Ⅱ级5例均未观察到剂量限制性毒性。
- 中位随访60个月,4年局部区域控制率为77.8%,4年总生存率为88.9%。
关键数值与推荐
- 奥拉帕利起始剂量为25 mg每日两次,联合放疗70 Gy/35次。
- 最大耐受剂量定义为不超过20%患者出现剂量限制性毒性的最高剂量水平,或在无剂量限制性毒性时达到的最高剂量。
- 剂量Ⅰ级:奥拉帕利25 mg每日两次联合加速放疗70 Gy/6周,4例中3例出现剂量限制性毒性。
- 剂量Ⅱ级:奥拉帕利25 mg每日一次联合常规分割放疗70 Gy/7周,5例均未出现剂量限制性毒性,确定为最大耐受剂量。
临床怎么用
- 作者认为该联合方案可在不适合顺铂为基础放化疗的局部晚期头颈部鳞状细胞癌患者的未来奥拉帕利剂量递增研究中进一步探索。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: PARP-inhibitors have potent radiosensitizing properties in pre-clinical models. To identify the maximum tolerated dose (MTD) of the PARP-inhibitor Olaparib in combination with radiotherapy in patients with head and neck cancer, a single institutional phase-I dose escalation trial was initiated. PATIENTS AND METHODS: The starting dose of Olaparib was 25 mg BID, combined with radiotherapy (70 Gy in 35 fractions). The MTD was defined as the highest dose-level at which not more than 20 % of patients experience dose-limiting toxicities (DLT) or as the highest reached dose in the absence of DLT's. RESULTS: One week Olaparib-only treatment (25 mg QD) was administered to all patients prior to the start of radiotherapy. In dose-level I, Olaparib (25 mg BID) was combined with accelerated radiotherapy (70 Gy in 6 weeks). Because of DLT's in 3 of the 4 treated patients (acute tracheotomy 5 and 7 months and osteoradionecrosis 7 months after treatment), the Olaparib dose was de-escalated to 25 mg QD, and combined with conventional radiotherapy (70 Gy in 7 weeks) (dose-level II). There were no DLT's observed in 5 patients treated within dose-level II. After a median follow-up of 60 months, the 4-year LRC and OS rates were 77.8 % and 88.9 %, respectively. CONCLUSION: Olaparib 25 mg QD combined with conventionally fractionated radiotherapy was well tolerated and identified as the MTD while severe DLT's were observed when Olaparib 25 mg BID was combined with accelerated radiation. This combination might be further explored in future Olaparib dose escalation studies in patients with locally-advanced HNSCC unfit for cisplatin-based chemoradiotherapy.
引用
- Navran A, Al-Mamgani A, Elzinga H, et al. Phase I feasibility study of Olaparib in combination with loco-regional radiotherapy in head and neck squamous cell carcinoma. Clin Transl Radiat Oncol. 2023. PMID: 38021094. doi:10.1016/j.ctro.2023.100698
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。